Techno Trends
AvidBiotics receives SBIR grant to develop protein antibacterial technology
AvidBiotics has received new Small Business Innovation Research (SBIR) grant from the National Institute of Allergic and Infectious Diseases of the National Institutes of Health to further develop targetable bactericidal proteins to kill Clostridium difficile bacteria. ...
Techno Trends
NICE recommends new drug to treat blood clots
Venous thromboembolism (VTE) is the term used to describe a condition in which a blood clot (a thrombus) forms in a vein and then dislodges to travel in the blood (an embolus). A venous thrombus most commonly occurs...
Techno Trends
New Technology to monitor crystal formation
Researchers at the University of Leeds have come up with a technology that could help the pharmaceutical industry in controlling crystal formation during the process of drug development. Pharmaceuticals often come in the crystalline forms and...
Techno Trends
Biochip to simplify drug development safety studies
Researchers at Rensselaer Polytechnic Institute in Troy, N.Y., the University of California, Berkeley, and Solidus Biosciences, Inc. have come up with a biochip technology that would accelerate the drug development safety studies with a simultaneous reduction in the...
Techno Trends
Disincentives to Adopting New Drug Delivery Systems
Scientists from the University of Syracuse chemistry department recently created a new drug delivery system which uses gold nanoparticles with attached DNA designed to bind to Doxorubin, an anticancer drug. The system allows for a large number of...
Techno Trends
Medicago to develop new VLP vaccine candidate for rabies
Medicago, a biotechnology company, has completed initial studies towards the development of a new VLP vaccine candidate for rabies. The initial studies with rabies VLP vaccine demonstrated that two doses of one or four...
Techno Trends
Oral therapy with Teriflunomide reduces relapses in multiple sclerosis
Sanofi and its subsidiary Genzyme has announced new data from the TEriflunomide multiple sclerosis oral (TEMSO) phase III trial showing once-daily oral teriflunomide significantly reduced annualized rates of relapses leading to hospitalization. New data also confirmed the safety profile...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















